Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 1
1938 1
1951 1
1953 3
1954 1
1963 1
1966 1
1969 1
1976 1
1978 1
1979 2
1984 1
1985 1
1987 1
1989 5
1990 4
1991 1
1992 2
1993 1
1994 11
1995 9
1996 4
1997 3
1998 6
1999 4
2000 7
2001 4
2002 3
2003 6
2004 5
2005 4
2006 10
2007 2
2008 12
2009 19
2010 22
2011 25
2012 19
2013 23
2014 29
2015 27
2016 28
2017 30
2018 33
2019 31
2020 42
2021 31
2022 46
2023 31
2024 30
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

543 results

Results by year

Filters applied: . Clear all
Page 1
Sickle cell disease.
Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Ware RE, et al. Among authors: abboud mr. Lancet. 2017 Jul 15;390(10091):311-323. doi: 10.1016/S0140-6736(17)30193-9. Epub 2017 Feb 1. Lancet. 2017. PMID: 28159390 Review.
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. Vichinsky E, et al. Among authors: abboud mr. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. N Engl J Med. 2019. PMID: 31199090 Clinical Trial.
Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.
Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, Ware RE, Abboud MR, Abraham A, Ambrose EE, Andemariam B, Colah R, Colombatti R, Conran N, Costa FF, Cronin RM, de Montalembert M, Elion J, Esrick E, Greenway AL, Idris IM, Issom DZ, Jain D, Jordan LC, Kaplan ZS, King AA, Lloyd-Puryear M, Oppong SA, Sharma A, Sung L, Tshilolo L, Wilkie DJ, Ohene-Frempong K. Piel FB, et al. Among authors: abboud mr. Lancet Haematol. 2023 Aug;10(8):e633-e686. doi: 10.1016/S2352-3026(23)00096-0. Epub 2023 Jul 11. Lancet Haematol. 2023. PMID: 37451304 Free PMC article. Review.
Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).
Osunkwo I, Andemariam B, Minniti CP, Inusa BPD, El Rassi F, Francis-Gibson B, Nero A, Trimnell C, Abboud MR, Arlet JB, Colombatti R, de Montalembert M, Jain S, Jastaniah W, Nur E, Pita M, DeBonnett L, Ramscar N, Bailey T, Rajkovic-Hooley O, James J. Osunkwo I, et al. Among authors: abboud mr. Am J Hematol. 2021 Apr 1;96(4):404-417. doi: 10.1002/ajh.26063. Epub 2021 Feb 25. Am J Hematol. 2021. PMID: 33264445 Free PMC article.
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.
Abboud MR, Cançado RD, De Montalembert M, Smith WR, Rimawi H, Voskaridou E, Güvenç B, Ataga KI, Keefe D, Grosch K, Watson J, Reshetnyak E, Nassin ML, Dei-Adomakoh Y. Abboud MR, et al. Lancet Haematol. 2025 Apr;12(4):e248-e257. doi: 10.1016/S2352-3026(24)00384-3. Epub 2025 Mar 12. Lancet Haematol. 2025. PMID: 40088922 Clinical Trial.
Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.
Idowu M, Otieno L, Dumitriu B, Lobo CLC, Thein SL, Andemariam B, Nnodu OE, Inati A, Glaros AK, Bartolucci P, Colombatti R, Taher AT, Abboud MR, Darbari D, Ataga KI, Antmen AB, Kuo KHM, de Souza Medina S, Oluyadi A, Iyer V, Morris S, Yates AM, Shao H, Patil S, Urbstonaitis R, Zaidi AU, Gheuens S, Smith WR. Idowu M, et al. Among authors: abboud mr. Lancet Haematol. 2025 Jan;12(1):e35-e44. doi: 10.1016/S2352-3026(24)00319-3. Epub 2024 Dec 4. Lancet Haematol. 2025. PMID: 39644907 Clinical Trial.
Hemoglobinopathies (Sickle Cell Disease and Thalassemia).
Cappelli B, Gluckman E, Ghanem K, Abboud MR. Cappelli B, et al. Among authors: abboud mr. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 79. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 79. PMID: 32091749 Free Books & Documents. Review.
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Åstrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR. Heeney MM, et al. Among authors: abboud mr. Blood. 2022 Sep 29;140(13):1470-1481. doi: 10.1182/blood.2021014095. Blood. 2022. PMID: 35849650 Free PMC article. Clinical Trial.
543 results